NEW YORK, June 16 /PRNewswire-FirstCall/ - Genesis Bioventures, Inc. (GBI) (OTCBB:GBIW - News) today announced that it has granted an exclusive license to Bio Business Development Company (BBDC) to commercialize the Rapid Prion Detection Assays in eighteen countries of the Pacific Rim. The licensed technology has been developed by Prion Developmental Laboratories (PDL), a portfolio company of GBI.
